Cargando…
Rationale and design of a stepped wedge cluster randomised trial to improve acute reperfusion treatment quality for stroke: IMPROVE stroke care in China
BACKGROUND: Reperfusion therapy is the most effective treatment for acute ischaemic stroke (AIS) but remains underutilised in China. There is an urgent need to develop tailored strategies to increase adherence to intravenous thrombolysis (IVT) and endovascular thrombectomy (EVT) within the guideline...
Autores principales: | Li, Zixiao, Wang, Chunjuan, Zhang, Xinmiao, Zong, Lixia, Zhou, Hongyu, Gu, Hongqiu, Jiang, Yong, Pan, Yuesong, Meng, Xia, Zhou, Qi, Zhao, Haifen, Yang, Xin, Wang, Meng, Xiong, Yunyun, Zhao, Xingquan, Wang, Yilong, Liu, Liping, Ma, Xudong, Morgan, Louise, Xian, Ying, Schwamm, Lee H, Wang, Yongjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614172/ https://www.ncbi.nlm.nih.gov/pubmed/35354662 http://dx.doi.org/10.1136/svn-2021-001461 |
Ejemplares similares
-
Rationale and design of Patient-centered Retrospective Observation of Guideline-Recommended Execution for Stroke Sufferers in China: China PROGRESS
por: Li, Zixiao, et al.
Publicado: (2019) -
Chinese Stroke Center Alliance: a national effort to improve healthcare quality for acute stroke and transient ischaemic attack: rationale, design and preliminary findings
por: Wang, Yongjun, et al.
Publicado: (2018) -
Intravenous thrombolysis in Chinese patients with mild acute ischemic stroke
por: Xiong, Yunyun, et al.
Publicado: (2021) -
The Third China National Stroke Registry (CNSR-III) for patients with acute ischaemic stroke or transient ischaemic attack: design, rationale and baseline patient characteristics
por: Wang, Yongjun, et al.
Publicado: (2019) -
The design, rationale, and baseline characteristics of a nationwide cohort registry in China: blood pressure and clinical outcome in TIA or ischemic stroke
por: Xu, Jie, et al.
Publicado: (2016)